

Information Governance Department
Suite 9
Buckingham Row
Brick Kiln Lane
Wigan
WN1 1XX

Email: foi@wwl.nhs.uk
Web: www.wwl.nhs.uk

Ref: FOI/2023/9145

Date Received: 18th August 2023

Response Due: 18th September 2023

Date: 15th September 2023

Dear Sir/Madam

You asked:

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of May 2023 to the end of July 2023 (or the latest available 3 months).

Appendix A

Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Months used = Jun-23 to Aug-23 inclusive

Data is from homecare patients as inpatients do not have the indication recorded on the pharmacy systems. There are low numbers of patients treated with these drugs at the hospital and most are homecare.

The drugs/indications where this may be relevant and shaded in yellow

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. Axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	17	<5	0	23	17	<5
Adalimumab (Biosimilars)	5	133	47	40	30	

Apremilast	<5			<5		
Bimekizumab	24					
Brodalumab	0					
Certolizumab Pegol	<5			5	6	12
Deucravacitinib	0					
Etanercept (Enbrel)	<5			10	8	10
Etanercept (Biosimilars)	0			21	26	106
Guselkumab	51			0		
Infliximab (Remicade)	0	0	0	0	0	0
Infliximab (Biosimilars)	0	20	9	0	0	0
Ixekizumab	<5			<5	0	
Risankizumab	36	0		0		
Secukinumab	21			14	10	
Tildrakizumab	<5					
Ustekinumab	24	74	24	5		
Upadacitinib		0	8	0	0	<5
Vedolizumab		52	46			
Filgotinib			3			7
Golimumab			0	13	5	<5
Mirikizumab			0			
Ozanimod			0			
Tofacitinib			0	0	0	0
Abatacept						13
Baricitinib						14
Rituximab						0
Sarilumab						0
Tocilizumab						35

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023? Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.

Months used = Jun-23 to Aug-23 inclusive

Data is from homecare patients and patients supplied directly from the hospital pharmacy departments.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	17	<5	50
Adalimumab (biosimilars)	5	182	120
Apremilast	<5	0	<5
Bimekizumab	24	0	0
Brodalumab	0	0	0
Certolizumab Pegol	<5	0	26
Deucravacitinib	0	0	0
Etanercept (Enbrel)	<5	0	32
Etanercept (Biosimilars)	0	0	167
Guselkumab	51	0	5
Infliximab (Remicade)	0	0	<5
Infliximab (Biosimilars)	0	62	0
Ixekizumab	<5	<5	0
Risankizumab	36	0	0
Secukinumab	21	0	24
Tildrakizumab	<5	0	0
Ustekinumab	24	112	5
Upadacitinib	<5	8	<5
Vedolizumab	0	163	0
Filgotinib	0	<5	7
Golimumab	0	0	21
Mirikizumab	0	0	0
Ozanimod	0	0	0
Tofacitinib	0	<5	<5
Abatacept	0	0	13
Baricitinib	0	0	14
Rituximab	0	0	36
Sarilumab	0	0	0
Tocilizumab	0	0	67

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- c) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- d) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Masterman', with a long horizontal line extending to the right.

Gary Masterman
Deputy Chief Pharmacist

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111